SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001104659-21-051971
Filing Date
2021-04-19
Accepted
2021-04-19 16:17:39
Documents
3

Document Format Files

Seq Description Document Type Size
1 DEFA14A tm2112429d3_defa14a.htm DEFA14A 28134
2 GRAPHIC tm2112429d3_defa14aimg001.jpg GRAPHIC 632926
3 GRAPHIC tm2112429d3_defa14aimg002.jpg GRAPHIC 241311
  Complete submission text file 0001104659-21-051971.txt   1233645
Mailing Address 99 HAYDEN AVENUE, SUITE 120 (BLD E) LEDGEMONT TECHNOLOGY CENTER LEXINGTON MA 02421
Business Address 99 HAYDEN AVENUE, SUITE 120 (BLD E) LEDGEMONT TECHNOLOGY CENTER LEXINGTON MA 02421 617-513-8774
Keros Therapeutics, Inc. (Filer) CIK: 0001664710 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-39264 | Film No.: 21834814
SIC: 2834 Pharmaceutical Preparations